Indian stocks: Visit www.stage2stocks.com →

BioRestorative Therapies, Inc.

Stage 2 · Advancing · week 6

As of Oct 22, 2026, BioRestorative Therapies is in Stage 2, the uptrend phase, now in week 6 (since Sep 16, 2026). It closed at $1.50, 46.6% below its 52-week high and above its 200-day average, which is rising.

BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. More about the company

$1.50
-1.96% today
$2.1M · Micro cap
Market Neutral — Building

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 110 in Biotechnology · #1 of 272 in Health Care

Is BRTX early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 15w
S4 25w
S4 16w
S4 28w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S3 1w → S4 15w → S1 2w → S4 25w → S1 6w → S2 6w → S3 5w → S2 5w → S3 5w → S4 4w → S1 1w → S2 10w → S3 7w → S2 4w → S3 1w → S4 16w → S1 3w → S4 28w → S1 11w → S4 4w → S1 1w → S2 5w current
Total tracked: 164 weeks across 22 stage runs.

BRTX among Biotechnology205th of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
…205BRTXStage 2 · wk 649−42.3%
vs 52W High
-46.6%
$0.14 lo$2.81 hi
46.6% below 52W high
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 6
1w13w26w
Week 6, early Stage 2
How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.
vs 200 DMA
115.9%
200 DMA: $0.69 · rising
Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.
Rel Volume
0.03x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-42.3%
3M
+417.2%
6M
+573.2%
YTD
+23.0%
1Y
-5.7%
Scan Membership
Breakout Watch
Latest: 2025-05-28
7 appearances in last 60 days. First seen: 2020-09-09.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S2
Wk 6 · Vol 0.03x
2026-10-21S2
Wk 6 · Vol 0.06x
2026-10-20S2
Wk 5 · Vol 0.09x
2026-10-19S2
Wk 5 · Vol 0.10x
2026-10-16S2
Wk 5 · Vol 0.11x
2026-10-15S2
Wk 5 · Vol 0.14x
2026-10-14S2
Wk 5 · Vol 0.09x
2026-10-13S2
Wk 4 · Vol 0.15x
2026-10-12S2
Wk 4 · Vol 0.05x
2026-10-09S2
Wk 4 · Vol 0.07x
2026-10-08S2
Wk 4 · Vol 0.37x
2026-10-07S2
Wk 4 · Vol 0.14x
Moving averages & range
50 DMA
$1.53
200 DMA
$0.69
52W High
$2.81
52W Low
$0.14
5D Low
$1.50
Resistance levels (recent highs)
20d High
$2.55
60d High
$2.81
120d High
$2.81
250d High
$2.81
Next resistance
+70.0%
to 20d High
ROE
-241.1%
Profit margin 0.0%
Dividend Yield
0.00%
P/B 0.6

BioRestorative Therapies: quick answers

What stage is BioRestorative Therapies in?

As of Oct 22, 2026, BioRestorative Therapies (BRTX) is in Stage 2, the uptrend phase. It entered Stage 2 on Sep 16, 2026 and is in week 6. What the four stages mean

Is BioRestorative Therapies in an uptrend?

Yes. BioRestorative Therapies is in a Stage 2 uptrend. It trades 115.9% above its 200-day average, which is rising.

How far is BioRestorative Therapies from its 52-week high?

BioRestorative Therapies closed at $1.50 on Oct 22, 2026, 46.6% below its 52-week high of $2.81. Its 52-week low is $0.14.

How has BioRestorative Therapies performed over the past year?

As of Oct 22, 2026, BioRestorative Therapies is down 5.7% over the past year and up 23.0% so far in 2026.

Which sector and industry is BioRestorative Therapies in?

BioRestorative Therapies is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. The company develops programs related to the treatment of disc/spine disease and metabolic disorders. Its products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, as well as used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure; and ThermoStem, a cell-based therapy candidate to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. The company also operates a commercial biocosmeceutical platform. In addition, it provides investigational curved needle device to deliver cells and/or other therapeutic products or material to the spine and discs, and other parts of the body. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. is headquartered in Melville, New York.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.